Literature DB >> 19415721

Clinical and laboratory diagnosis of von Willebrand disease: a synopsis of the 2008 NHLBI/NIH guidelines.

William L Nichols1, Margaret E Rick, Thomas L Ortel, Robert R Montgomery, J Evan Sadler, Barbara P Yawn, Andra H James, Mae B Hultin, Marilyn J Manco-Johnson, Mark Weinstein.   

Abstract

Von Willebrand factor (VWF) mediates blood platelet adhesion and accumulation at sites of blood vessel injury, and also carries coagulation factor VIII (FVIII) that is important for generating procoagulant activity. Von Willebrand disease (VWD), the most common inherited bleeding disorder, affects males and females, and reflects deficiency or defects of VWF that may also cause decreased FVIII. It may also occur less commonly as an acquired disorder (acquired von Willebrand syndrome). This article briefly summarizes selected features of the March 2008 evidence-based clinical and laboratory diagnostic recommendations from the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel for assessment for VWD or other bleeding disorders or risks. Management of VWD is also addressed in the NHLBI guidelines, but is not summarized here. The VWD guidelines are available at the NHLBI Web site (http://www.nhlbi.nih.gov/guidelines/vwd).

Entities:  

Mesh:

Year:  2009        PMID: 19415721      PMCID: PMC5592788          DOI: 10.1002/ajh.21405

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  8 in total

1.  Functional impairment of von Willebrand factor in hypertrophic cardiomyopathy: relation to rest and exercise obstruction.

Authors:  Thierry Le Tourneau; Sophie Susen; Claudine Caron; Alain Millaire; Sylvestre Maréchaux; Anne-Sophie Polge; André Vincentelli; Frederic Mouquet; Pierre-Vladimir Ennezat; Nicolas Lamblin; Pascal de Groote; Eric Van Belle; Ghislaine Deklunder; Jenny Goudemand; Christophe Bauters; Brigitte Jude
Journal:  Circulation       Date:  2008-09-22       Impact factor: 29.690

2.  Abnormal von Willebrand factor in bleeding angiodysplasias of the digestive tract.

Authors:  A Veyradier; A Balian; M Wolf; V Giraud; S Montembault; B Obert; I Dagher; J C Chaput; D Meyer; S Naveau
Journal:  Gastroenterology       Date:  2001-02       Impact factor: 22.682

Review 3.  Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor.

Authors:  J E Sadler; U Budde; J C J Eikenboom; E J Favaloro; F G H Hill; L Holmberg; J Ingerslev; C A Lee; D Lillicrap; P M Mannucci; C Mazurier; D Meyer; W L Nichols; M Nishino; I R Peake; F Rodeghiero; R Schneppenheim; Z M Ruggeri; A Srivastava; R R Montgomery; A B Federici
Journal:  J Thromb Haemost       Date:  2006-08-02       Impact factor: 5.824

4.  Diagnostic workup of patients with acquired von Willebrand syndrome: a retrospective single-centre cohort study.

Authors:  A Tiede; J Priesack; S Werwitzke; K Bohlmann; B Oortwijn; P Lenting; R Eisert; A Ganser; U Budde
Journal:  J Thromb Haemost       Date:  2008-01-17       Impact factor: 5.824

5.  Non-surgical bleeding in patients with ventricular assist devices could be explained by acquired von Willebrand disease.

Authors:  Ulrich Geisen; Claudia Heilmann; Friedhelm Beyersdorf; Christoph Benk; Michael Berchtold-Herz; Christian Schlensak; Ulrich Budde; Barbara Zieger
Journal:  Eur J Cardiothorac Surg       Date:  2008-02-20       Impact factor: 4.191

Review 6.  Guidelines on the assessment of bleeding risk prior to surgery or invasive procedures. British Committee for Standards in Haematology.

Authors:  Y L Chee; J C Crawford; H G Watson; M Greaves
Journal:  Br J Haematol       Date:  2008-03       Impact factor: 6.998

7.  Occult gastrointestinal bleeding due to acquired von Willebrand syndrome in a patient with hypertrophic obstructive cardiomyopathy.

Authors:  Masatoshi Shimizu; Hiroyuki Masai; Yoichi Miwa
Journal:  Intern Med       Date:  2007-04-17       Impact factor: 1.271

8.  von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA).

Authors:  W L Nichols; M B Hultin; A H James; M J Manco-Johnson; R R Montgomery; T L Ortel; M E Rick; J E Sadler; M Weinstein; B P Yawn
Journal:  Haemophilia       Date:  2008-03       Impact factor: 4.287

  8 in total
  19 in total

1.  Generation and optimization of the self-administered bleeding assessment tool and its validation as a screening test for von Willebrand disease.

Authors:  M Deforest; J Grabell; S Albert; J Young; A Tuttle; W M Hopman; P D James
Journal:  Haemophilia       Date:  2015-07-14       Impact factor: 4.287

2.  Hypertrophic obstructive cardiomyopathy, acquired von Willebrand syndrome, and gastrointestinal bleeding.

Authors:  Rajiv K Pruthi
Journal:  Mayo Clin Proc       Date:  2011-03       Impact factor: 7.616

3.  Recommendations for the transfusion management of patients in the peri-operative period. I. The pre-operative period.

Authors:  Giancarlo Maria Liumbruno; Francesco Bennardello; Angela Lattanzio; Pierluigi Piccoli; Gina Rossetti
Journal:  Blood Transfus       Date:  2011-01       Impact factor: 3.443

4.  Tolvaptan inhibition of desmopressin effects on coagulation factors in a patient with decreased von Willebrand factor and polycystic kidney disease.

Authors:  Jon D Blumenfeld; Jeffrey Tepler; Andreas Mauer; Barry Coller; Daniel G Bichet; Barry Smith
Journal:  Blood       Date:  2011-07-14       Impact factor: 22.113

5.  New advances in the diagnosis of von Willebrand disease.

Authors:  Ruchika Sharma; Sandra L Haberichter
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

6.  Misfolding of vWF to pathologically disordered conformations impacts the severity of von Willebrand disease.

Authors:  Alexander Tischer; Pranathi Madde; Laurie Moon-Tasson; Matthew Auton
Journal:  Biophys J       Date:  2014-09-02       Impact factor: 4.033

7.  Hypertrophic obstructive cardiomyopathy, bleeding history, and acquired von Willebrand syndrome: response to septal myectomy.

Authors:  Joseph L Blackshear; Hartzell V Schaff; Steve R Ommen; Dong Chen; William L Nichols
Journal:  Mayo Clin Proc       Date:  2011-03       Impact factor: 7.616

Review 8.  Historical perspective and future directions in platelet research.

Authors:  B S Coller
Journal:  J Thromb Haemost       Date:  2011-07       Impact factor: 5.824

Review 9.  Women and bleeding disorders: diagnostic challenges.

Authors:  Paula D James
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

Review 10.  Current controversies in the diagnosis and management of von Willebrand disease.

Authors:  Anne T Neff
Journal:  Ther Adv Hematol       Date:  2015-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.